Mechanistic models for myelosuppression.
As myelosuppression is the dose-limiting toxicity for most chemotherapeutic drugs, modelers attempt to find relationships between drug and toxicity to optimize treatment. Mechanistic models, i.e. models based on physiology and pharmacology, are preferable over empirical models, as prior information can be utilized and as they generally are more reliable for extrapolations. To account for different dosing-regimens and possible schedule-dependent effects, the whole concentration-time profile should be used as input into the pharmacokinetic-pharmacodynamic model. It is also of importance to model the whole time course of myelosuppression to be able to predict both the degree and duration of toxicity as well as consecutive courses of therapy. A handful of (semi)-mechanistic pharmacokinetic-pharmacodynamic models with the above properties have been developed and are reviewed. Ideally, a model of myelosuppression should separate drug-specific parameters from system related parameters to be applicable across drugs and useful under different clinical settings. Introduction of mechanistic models of myelosuppression in the design and evaluation of clinical trials can guide in the decision of optimal sampling times, contribute to knowledge of optimal doses and treatment regimens at an earlier time point and identify sub-groups of patients at a high risk of myelosuppression.
Friberg
Lena E
LE
Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden. Lena.Friberg@farmbio.uu.se
Karlsson
Mats O
MO
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008954:Models, Biological; D038042:Myelopoiesis / Q000187:drug effects* / Q000502:physiology; D009503:Neutropenia / Q000139:chemically induced*; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology
D000970:Antineoplastic Agents